ASX-listed biotechnology company Cynata Therapeutics has sealed a partnership agreement with Fujifilm as it makes a big step towards a commercial manufacturing deal for its proprietary Cymerus stem cell therapy products and eyes an accelerated push into the all-important United States drug market. The company is planning a stage two trial of the therapy to treat bone marrow recipients.
